As the NHS Cervical Screening Programme (NHSCSP) rolls out high-risk human papillomavirus (HR-HPV) testing for the triage of women with borderline or low-grade cervical abnormalities across England, women around the country are already benefiting from faster treatment and potentially life-saving outcomes thanks to the Roche cobas HPV test.
Currently, only five commercially available HPV tests have been approved, including the cobas HPV test. The cobas HPV test is also the only integrated genotyping test to have undergone full clinical validation. The Roche cobas HPV test is now available in more than 30 NHS laboratories.
The automated cobas HPV test is ideal for screening large numbers of samples for HR-HPV. Unlike other HPV assays, this is a US Food and Drug Administration (FDA)-approved and CE-marked test that provides a separate result for the highest risk HPV genotypes (HPV16 and HPV18), in addition to a pooled result for all HR-HPV genotypes. This separate, simultaneous detection of HPV16 and HPV18 assists clinicians in risk stratification, allowing women who may need more intensive follow-up and intervention to be identified.
www.roche.co.uk